论文部分内容阅读
目的了解肺炎支原体(MP)耐大环内酯类抗菌药物情况及主要的耐药机制。方法从32例因MP引起呼吸道感染的患儿取咽拭子,采用改良Hayflick培养基分离培养;运用药物敏感试验筛选耐大环内酯类抗菌药物的耐药株;聚合酶链反应(PCR)扩增结合序列测定分析耐药分子机制。结果32份标本培养成功19份;药敏结果显示19株MP临床分离株中有15株耐药,占78.9%,而且一旦对其中1种药物耐药,对其他大环内酯类抗菌药物也均呈耐药性;敏感株和标准株FH的测序结果完全相同,15株耐药株23SrRNAⅤ区均出现了A2063G的点突变,其中有2株为敏感株和耐药株共生。结论MP对大环内酯类抗菌药物耐药现状严重,其主要的耐药机制为23S rRNAⅤ区产生点突变。
Objective To understand the situation and main mechanism of resistance to macrolide antibiotics in Mycoplasma pneumoniae (MP). Methods Thirty-two throat swabs were collected from children with respiratory tract infection caused by MP and cultured in modified Hayflick medium. Drug-resistant strains were screened for resistance to macrolide-resistant antibiotics. Polymerase chain reaction (PCR) Amplification of binding sequence analysis of drug resistance molecular mechanism. Results 32 samples were successfully cultivated in 19 samples. The susceptibility results showed that 15 of the 19 MP clinical isolates were resistant, accounting for 78.9% of the total isolates. Once one of these drugs was resistant, other macrolide antibiotics The results of sequencing of sensitive strain and standard strain FH were identical. Point mutation of A2063G appeared in 23SrRNAⅤ region of 15 drug-resistant strains, of which 2 strains were symbiotic with sensitive strains and drug-resistant strains. Conclusion The present situation of MP resistance to macrolide antibiotics is serious. The main mechanism of drug resistance is point mutation in 23S rRNAⅤ region.